University of Nottingham

Promethean Particles Ltd. is a company based in Nottingham, United Kingdom, specializing in the design, development, and manufacture of inorganic nanoparticle dispersions. Incorporated in 2007, it utilizes continuous hydrothermal synthesis to produce bespoke products tailored to specific customer applications across various industries, including electronics, healthcare, green energy, and nanocomposites. The company operates a state-of-the-art multi-ton scale manufacturing facility capable of producing over 1,000 tons per year, which supports its ability to deliver customized solutions. Promethean Particles also offers feasibility studies and reactor designs, showcasing its significant expertise and patented technology in nanoparticle production. This unique combination of capabilities allows the company to meet diverse industrial needs, enhancing flexibility and innovation in the development of nanotechnology solutions.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

PBD Biotech Ltd., established in 2014 and headquartered in Thurston, UK, specializes in the development of innovative phage-based diagnostic technology for veterinary diagnostics. The company focuses on detecting mycobacterial infections such as Mycobacterium bovis (bovine TB) and Mycobacterium avium subsp. paratuberculosis (MAP), which significantly impact agricultural productivity. PBD Biotech's proprietary Actiphage platform enables rapid, accurate detection of these pathogens in milk and blood samples, differentiating viable bacteria from non-viable ones, thereby aiding clinicians in early diagnosis and effective management of these diseases.

Operator of a biotechnology company intended to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company aims for therapeutic applications in diseases with high unmet clinical needs such as fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), liver and kidney disease and cancer, enabling patients affected by life-limiting conditions to access effective treatments and relief.

Cheesecake Energy specializes in the development of advanced thermal and compressed air energy systems aimed at storing energy generated from intermittent renewable sources. By transforming this energy into reliable, on-demand power, the company addresses the challenges of energy supply consistency. Their innovative technology utilizes compressed air and thermal energy storage methods, which leverage industrial components that are readily available in the market. This approach not only enhances the efficiency of energy storage but also allows clients to acquire durable storage solutions at competitive prices.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories is a company focused on facilitating language learning for children through engaging storytelling. By employing their innovative Clockwork Methodology®, One Third Stories creates a unique experience where stories begin in English and transition into different languages, making the learning process enjoyable and accessible. The company offers a subscription box service that delivers these stories to parents and their children, enabling them to embark on a language learning adventure together. Through this approach, One Third Stories aims to make foreign language acquisition simple and fun for young learners.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories is a company focused on facilitating language learning for children through engaging storytelling. By employing their innovative Clockwork Methodology®, One Third Stories creates a unique experience where stories begin in English and transition into different languages, making the learning process enjoyable and accessible. The company offers a subscription box service that delivers these stories to parents and their children, enabling them to embark on a language learning adventure together. Through this approach, One Third Stories aims to make foreign language acquisition simple and fun for young learners.

Monica Healthcare, based in Nottingham, United Kingdom, is a manufacturer of advanced fetal monitoring devices aimed at improving obstetric care. Founded in 2005, the company specializes in innovative wearable technologies that utilize wireless systems to monitor maternal heart rate, fetal heart rate, and uterine activity. One of its key products is The Novii, a single-use wireless patch designed for both hospital and home use. Monica Healthcare's devices are intended to enhance the birth experience for midwives, labor and delivery nurses, and expectant mothers, while also facilitating access to obstetric services. In addition to its product offerings, the company provides training, repairs, and support services to its customers. Since 2017, Monica Healthcare has been operating as a subsidiary of GE Healthcare.

Exonate Limited is a privately held biotech company founded in 2013 and based in Duxford, United Kingdom, with a research and development laboratory in Nottingham. The company specializes in the discovery and development of small molecule drugs that target alternative messenger RNA splicing, particularly in the field of ophthalmology. Exonate's lead program focuses on diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), significant causes of vision loss. The company has developed a pipeline of novel small molecule inhibitors, known as SPHINXes, which selectively inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the modulation of serine/threonine-protein kinase 1 (SRPK1)-mediated splicing. These inhibitors have shown promising efficacy in preclinical models as topical agents for treating these retinal disorders. Exonate is backed by a strong scientific foundation and leadership team, with connections to academic expertise at the University of Nottingham. The company is advancing its drug candidates through regulatory studies aimed at clinical evaluation.

Monica Healthcare, based in Nottingham, United Kingdom, is a manufacturer of advanced fetal monitoring devices aimed at improving obstetric care. Founded in 2005, the company specializes in innovative wearable technologies that utilize wireless systems to monitor maternal heart rate, fetal heart rate, and uterine activity. One of its key products is The Novii, a single-use wireless patch designed for both hospital and home use. Monica Healthcare's devices are intended to enhance the birth experience for midwives, labor and delivery nurses, and expectant mothers, while also facilitating access to obstetric services. In addition to its product offerings, the company provides training, repairs, and support services to its customers. Since 2017, Monica Healthcare has been operating as a subsidiary of GE Healthcare.

Critical Pharmaceuticals Limited is a biotechnology company based in Nottingham, United Kingdom, founded in 2002 by Professor Steve Howdle. The company specializes in developing innovative drug delivery technologies, including CriticalSorb for non-invasive nasal delivery and CriticalMix for sustained release injectable products. Its portfolio features several therapeutic products aimed at addressing significant medical needs, such as CP024, a nasal growth hormone for growth hormone deficiency, and CP046, a nasal formulation of teriparatide for osteoporosis treatment. Other products include an injectable human growth hormone and a sustained release formulation of Bevacizumab for age-related macular degeneration. Critical Pharmaceuticals employs unique methods, including the use of supercritical carbon dioxide to enhance drug encapsulation in regulatory-approved polymers. As of July 31, 2017, the company was placed under liquidation.